Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

epacadostat (INCB024360)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Incyte

Drug class:

IDO1 inhibitor

Related drugs:

‹

›

KRAS mutation	Lung Adenocarcinoma	KRAS mutation	Lung Adenocarcinoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3
IDO1 positive	Melanoma	IDO1 positive	Melanoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3
BRAF mutation	Melanoma	BRAF mutation	Melanoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3
PD-L1 expression	Melanoma	PD-L1 expression	Melanoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3